Back to top
more

Incyte (INCY)

(Delayed Data from NSDQ)

$68.06 USD

68.06
2,737,008

+1.96 (2.97%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $67.78 -0.28 (-0.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

    Incyte Treats First Patient in Phase II GVHD Study on Jakafi

    Incyte Corporation (INCY) announced that the first patient has been treated in the pivotal phase II REACH-1 study assessing its marketed drug Jakafi, in combination with corticosteroids, for the treatment of GVHD.

      Arpita Dutt headshot

      Two Key FDA Decisions to Watch Out for in January 2017

      Incyte (INCY) and Synergy (SGYP) have important regulatory events coming up this month.

        The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech

        The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech

          Incyte/Merus Ink Collaboration for Bispecific Antibodies

          Incyte (INCY) entered into an agreement with Merus (MRUS) to discover and develop bispecific antibodies using the latter's proprietary Biclonics technology platform.

            Incyte/Lilly Olumiant Wins CHMP Nod for Rheumatoid Arthritis

            Incyte (INCY) and Eli Lilly (LLY) announced that the EMA's CHMP has issued a positive opinion for the approval of Olumiant (baricitinib).

              Incyte Jakafi Positive in Pooled Analysis of Five-Year Data

              Incyte (INCY) announced pooled analysis of five-year data from two phase III studies on Jakafi, which support previous long-term results.

                Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors

                Agenus (AGEN) announced that it has dosed the first patient in a phase I/II study on INCAGN1949 for the treatment of patients with solid tumors.

                  Indradip Ghosh headshot

                  New Strong Buy Stocks for October 11th

                  Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

                    New Strong Buy Stocks for August 10th

                    Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

                      Kevin Matras headshot

                      A Company's First Profit Can Mean Big Profits to Investors

                      Kevin Matras screens for companies showing their 'first' profit, and explains why they are ones to watch. Highlighted stocks include OPHT, XNPT, OSUR, INCY and AGIO.